Becton Dickinson 배당 및 자사주 매입
배당 기준 점검 5/6
Becton Dickinson 수익으로 충분히 충당되는 현재 수익률 2.36% 보유한 배당금 지급 회사입니다. 다음 지급일은 30th September, 2026 이며 배당락일은 다음과 같습니다. 9th September, 2026.
핵심 정보
2.4%
배당 수익률
5.2%
자사주 매입 수익률
| 총 주주 수익률 | 7.6% |
| 미래 배당 수익률 | 2.2% |
| 배당 성장률 | 4.6% |
| 다음 배당 지급일 | 30 Sep 26 |
| 배당락일 | 09 Sep 26 |
| 주당 배당금 | n/a |
| 배당 성향 | 72% |
최근 배당 및 자사주 매입 업데이트
Recent updates
내러티브 업데이트 • Sep 05
BDX: Margin Execution And Capital Returns May Balance 2027 Utilization Concerns
Becton Dickinson's updated fair value estimate of about $196, compared with roughly $190 previously, reflects analysts' higher price targets in the $190 to $210 range and their focus on remaining margin opportunity, manufacturing scale, and potential for steadier mid single digit growth over time. Analyst Commentary Recent research on Becton Dickinson shows a mix of optimism and caution that centers on execution, margin potential, and how quickly growth goals can show up in reported results.
내러티브 업데이트 • Aug 22
BDX: 2027 Utilization And Inflation Headwinds Will Cap Medium Term Upside
Becton Dickinson's fair value estimate moves to $170 from $161 as analysts point to a slightly lower discount rate, less severe revenue pressure, stronger projected profit margins, and a lower future P/E assumption supported by recent price target increases across several research firms. Analyst Commentary Recent Street research on Becton Dickinson reflects a mix of optimism on the business model and caution on the pace of execution, especially over the next couple of years.Seeking Alpha • Aug 13
Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing
Summary Becton Dickinson gets its prior buy rating reaffirmed again, agreeing with the latest Wall St consensus. Key strengths are its diverse and growing clinical portfolio expected to drive further upside, while a favorable Fitch rating lowers balance sheet risk. Market performance vs the S&P 500 is improving again. Key sector risks such as regulations, recalls, and the cost of capex investment into R&D and infrastructure were addressed. Read the full article on Seeking Alpha내러티브 업데이트 • Aug 08
BDX: Q3 Execution And Capital Returns May Offset 2027 Utilization Risks
Becton Dickinson's analyst fair value estimate has moved higher by about $8 to $189.58 as analysts factor in recent price target increases, confidence in easing headwinds, and support from product growth drivers and capital allocation plans. Analyst Commentary Recent Street research on Becton Dickinson highlights a mix of optimism around execution and product-driven growth, alongside caution on utilization trends and longer-term margin pressure.내러티브 업데이트 • Jul 21
BDX: FY26 Utilization And Inflation Risks Will Temper Execution Upside
Analysts have adjusted the fair value estimate for Becton Dickinson stock from $150 to $161, citing updated views on sector procedure volumes, utilization trends, inflation headwinds, and valuation as reflected in recent changes to Street price targets. Analyst Commentary Recent Street commentary on Becton Dickinson reflects a mix of views, and several bearish analysts are leaning toward more cautious stances as they reassess utilization trends, inflation pressures, and how much optimism is already priced into the stock.내러티브 업데이트 • Jul 06
BDX: FY26 Execution And Utilization Risks Will Shape Balanced Outlook
Becton Dickinson's analyst fair value estimate has been revised down by $6 to $150 as analysts factor in slightly lower utilization expectations and more conservative longer term assumptions, even as they point to generally healthy procedure volumes and capital expenditure trends across the sector. Analyst Commentary Recent research on Becton Dickinson points to a more cautious tone, with several bearish analysts trimming price targets while still acknowledging generally healthy procedure volumes and capital expenditure trends across MedTech, Life Sciences Tools, and Diagnostics.
내러티브 업데이트 • Jun 22
BDX: Raised FY26 EPS Guidance And Buybacks Will Support Underappreciated Setup
The analyst price target for Becton Dickinson has been reduced by about $36 per share as analysts factor in lower utilization trends, inflation headwinds into 2027, and more limited margin expansion assumptions across larger medtech companies. Analyst Commentary Recent research on Becton Dickinson reflects a mixed backdrop, with several firms trimming price targets to account for lower utilization trends and inflation pressure into 2027.분석 기사 • Jun 19
Becton Dickinson (BDX) Stock Could Be 20.6% Undervalued After Class I Spinal Tray Recalls
Becton Dickinson (BDX) has initiated several voluntary Class I sub-recalls of BD Spinal Tray products across the US after FDA inspections flagged acceptance testing deficiencies at a supplier of bupivacaine in dextrose. See our latest analysis for Becton Dickinson. Becton Dickinson's share price has been under pressure, with the stock down 26.14% on a year to date share price return and 6.59% over 90 days, even though the 1 year total shareholder return is 11.34%. This suggests momentum has...내러티브 업데이트 • Jun 06
BDX: New Medtech Portfolio And Buybacks Will Support Future Repricing
The updated analyst price target narrative for Becton Dickinson reflects a reduction of about $11 per share. Analysts are balancing recent target cuts and rating resets with more moderate assumptions for profit margins and valuation multiples.내러티브 업데이트 • May 22
BDX: FY26 Execution And Margin Resets Will Shape Balanced Risk Profile
Analysts have trimmed the implied fair value for Becton Dickinson by $1 to $156, reflecting updated assumptions for slower revenue growth, lower profit margins, and a higher future P/E multiple following a series of recent price target cuts and one modest increase across the Street. Analyst Commentary Recent Street research on Becton Dickinson has leaned cautious, with several bearish analysts trimming price targets while only one major firm made a modest upward adjustment.분석 기사 • May 19
Shareholders Will Be Pleased With The Quality of Becton Dickinson's (NYSE:BDX) Earnings
The subdued stock price reaction suggests that Becton, Dickinson and Company's ( NYSE:BDX ) strong earnings didn't...내러티브 업데이트 • Apr 30
BDX: Cautious Reset In FY26 Expectations And Execution Risks Will Shape Outlook
Becton Dickinson's analyst price target has been reset from $183 to $157 as analysts factor in more cautious revenue growth, slightly softer profit margins, a higher discount rate, and a lower assumed future P/E multiple. Analyst Commentary Recent Street research around Becton Dickinson reflects a more cautious tone, with a series of price target resets and neutral stances shaping expectations for risk and reward.내러티브 업데이트 • Apr 15
BDX: 2026 MedTech Setup And Buybacks Will Support Upside Potential
Analyst price targets for Becton Dickinson have edged lower, with the fair value estimate moving from about $196.08 to $192.31 as analysts factor in slightly higher discount rates, modestly softer revenue growth and profit margins, and a somewhat higher future P/E multiple. Analyst Commentary Recent Street research on Becton Dickinson reflects a mix of optimism and caution, with several firms adjusting price targets and ratings as they reassess execution risks and valuation assumptions.내러티브 업데이트 • Apr 01
BDX: 2026 MedTech Setup And Tuck In M&A Will Support Upside
Analysts have trimmed their average price target for Becton Dickinson by about $1, reflecting slightly lower fair value and P/E assumptions, along with modestly higher profit margin expectations. Analyst Commentary Recent Street research on Becton Dickinson has featured several price target changes and rating actions that point to a mix of optimism about execution and caution around valuation and growth assumptions.내러티브 업데이트 • Mar 18
BDX: 2026 MedTech Setup And Tuck In M&A Will Drive Upside
Narrative Update The latest analyst work on Becton Dickinson points to a mixed shift in price targets, with some firms raising their views by $12.30 to $15.00 while others trimmed estimates by $1.00 to $38.00, as analysts reassessed near term pressures, longer term MedTech prospects into 2026, and valuation assumptions including discount rate and future P/E inputs. Analyst Commentary Recent Street research on Becton Dickinson points to a split view, with some analysts lifting targets and others trimming them as they rework models for 2025 pressures and the setup into 2026.내러티브 업데이트 • Mar 04
BDX: 2026 MedTech Setup And Buybacks Will Shape Upside Potential
The analyst price target for Becton Dickinson has been adjusted to approximately $197 from about $195, as analysts factor in recently updated views on large cap MedTech setups, leading to slightly higher fair value and P/E assumptions. Analyst Commentary Recent research on Becton Dickinson reflects a mix of optimism and caution, with several firms adjusting price targets and ratings as they reassess large cap MedTech names and Becton Dickinson's role within that group.내러티브 업데이트 • Feb 17
BDX: 2026 Reset With Mixed Research And Product Pipeline Will Shape Returns
Analysts have trimmed their average price target on Becton Dickinson by about $9 to reflect more cautious assumptions on revenue growth and margins. This is partly offset by a willingness to apply a higher future P/E multiple as recent research updates reset expectations across the sector.내러티브 업데이트 • Feb 03
BDX: FY26 Guidance Reset Will Support More Constructive 2026 MedTech Setup
Narrative update The analyst price target for Becton Dickinson has been revised from about US$322 to about US$253. Analysts cite updated assumptions for growth, margins and future P/E, and they also reflect mixed recent Street research that includes both target raises and cuts following FY26 guidance and Q4 results.분석 기사 • Jan 31
Becton Dickinson (NYSE:BDX) Will Pay A Dividend Of $1.05
Becton, Dickinson and Company's ( NYSE:BDX ) investors are due to receive a payment of $1.05 per share on 31st of...내러티브 업데이트 • Jan 19
BDX: FY26 Reset And Alaris China And Vaccine Headwinds Will Pressure Outlook
Analysts have modestly adjusted their price expectations for Becton Dickinson, with recent Street targets ranging from a reduction to $202 to an increase to $215. They are balancing near term headwinds in areas like Alaris, China, and vaccines against what some see as a more constructive setup heading into 2026 for large cap MedTech.내러티브 업데이트 • Jan 05
BDX: 2026 Reset And Headwinds Will Shape Fairly Balanced Return Potential
Analysts have modestly adjusted their fair value estimate for Becton Dickinson to about $205 per share, reflecting updated views on slower profit margin assumptions, a somewhat higher future P/E, and recent price target resets around $202 to $210 following Q4 results and FY26 guidance. Analyst Commentary Recent Street research has focused on how Becton Dickinson's latest Q4 results and FY26 outlook feed into valuation, execution risk, and growth expectations.내러티브 업데이트 • Dec 21
BDX: FY26 Reset And Business Separation Will Shape Balanced Risk Reward Outlook
We raise our fair value estimate for Becton Dickinson to $183 from $172 per share, reflecting analysts' view that a conservative FY26 reset, modestly higher long term profitability, and a slightly richer future earnings multiple more than offset near term revenue growth headwinds and higher risk premia embedded in the discount rate. Analyst Commentary Bearish analysts are converging around a more cautious outlook for Becton Dickinson, trimming price targets and highlighting execution risks that could cap near term upside.내러티브 업데이트 • Dec 07
BDX: 2026 Separation And Reset Outlook Will Shape Returns Amid Headwinds
Analysts have modestly lowered their price target on Becton Dickinson to about $203 per share from roughly $201 previously. This reflects slightly higher long term revenue growth assumptions, offset by a marginally lower profit margin outlook and cautious views on FY26 guidance amid Alaris, China, and vaccine related headwinds.분석 기사 • Nov 24
Becton Dickinson's (NYSE:BDX) Dividend Will Be Increased To $1.05
The board of Becton, Dickinson and Company ( NYSE:BDX ) has announced that it will be paying its dividend of $1.05 on...내러티브 업데이트 • Nov 23
BDX: Modest Guidance and 2026 Separation Will Shape Future Performance Amid Headwinds
Becton Dickinson's analyst price target was reduced from approximately $206.58 to $201.49. Analysts attribute this change to cautious forward guidance, modest revenue expectations, and ongoing external headwinds highlighted in recent reports.분석 기사 • Nov 16
Some Investors May Be Willing To Look Past Becton Dickinson's (NYSE:BDX) Soft Earnings
Soft earnings didn't appear to concern Becton, Dickinson and Company's ( NYSE:BDX ) shareholders over the last week. We...분석 기사 • Nov 09
Becton Dickinson (NYSE:BDX) Has Announced That It Will Be Increasing Its Dividend To $1.05
Becton, Dickinson and Company ( NYSE:BDX ) will increase its dividend on the 31st of December to $1.05, which is 1.0...내러티브 업데이트 • Nov 07
BDX Will Unlock New Growth Following Planned 2026 Business Separation
Becton Dickinson Analyst Price Target Narrative Update The analyst fair value estimate for Becton Dickinson was reduced slightly from $208 to approximately $206.58, with analysts citing a more conservative earnings outlook and limited growth expectations in the near term. Analyst Commentary Analyst perspectives on Becton Dickinson reflect a balanced view of the company’s near-term challenges and long-term opportunities.지급의 안정성과 성장
배당 데이터 가져오는 중
안정적인 배당: BDX 의 주당 배당금은 지난 10 년 동안 안정적이었습니다.
배당금 증가: BDX 의 배당금 지급은 지난 10 년 동안 증가했습니다.
배당 수익률 vs 시장
| Becton Dickinson 배당 수익률 vs 시장 |
|---|
| 구분 | 배당 수익률 |
|---|---|
| 회사 (BDX) | 2.4% |
| 시장 하위 25% (US) | 1.4% |
| 시장 상위 25% (US) | 4.1% |
| 업계 평균 (Medical Equipment) | 2.0% |
| 분석가 예측 (BDX) (최대 3년) | 2.2% |
주목할만한 배당금: BDX 의 배당금( 2.36% )은 US 시장에서 배당금 지급자의 하위 25%( 1.36% )보다 높습니다.
고배당: BDX 의 배당금( 2.36% )은 US 시장에서 배당금 지급자의 상위 25%( 4.11% )와 비교해 낮습니다.
주주 대상 이익 배당
수익 보장: 합리적인 지급 비율 ( 71.7% )을 통해 BDX 의 배당금 지급은 수익으로 충당됩니다.
주주 현금 배당
현금 흐름 범위: 합리적으로 낮은 현금 지급 비율 ( 44.2% )로 BDX 의 배당금 지급은 현금 흐름으로 잘 충당됩니다.
높은 배당을 제공하는 우량 기업 찾기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/11 16:45 |
| 종가 | 2026/09/11 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/09/30 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Becton, Dickinson and Company는 31명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Toung | Argus Research Company |
| Matthew Miksic | Barclays |
| Adam Feinstein | Barclays |